Cancer News and Research

Latest Cancer News and Research

Cincinnati Children's Hospital Medical Center launches REGID

A new nationwide registry will allow researchers to conduct larger, more effective studies of often misdiagnosed disorders that affect thousands of children in the United States.

19 May 2010

Researchers discover biological pathway signature of ccRCC

By examining expression of every human gene in clear cell renal cell carcinoma compared to normal kidney cells, researchers at Mayo Clinic's campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.

19 May 2010

Where are Australia’s missing hepatitis C cases?

Around 90% of those infected have not received treatment, despite the potential for cure, a report to coincide with National Hepatitis Week shows

18 May 2010

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

The Whittemore Peterson Institute for Neuro-Immune Disease (WPI) and Cerus Corporation announced positive results from a study demonstrating the efficacy of the INTERCEPT Blood System to inactivate XMRV, a human retrovirus, in donated platelet components.

18 May 2010

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Senesco Technologies, Inc. today announced that preclinical data for the Company's lead drug candidate, SNS-01, will be presented on May 20, 2010 at the American Society of Gene and Cell Therapy Annual Meeting being held at the Marriott Wardman Park Hotel in Washington, D.C. from May 17 to 22.

18 May 2010

Baptist Health System implements eGuardian eICU Program from Philips VISICU

Baptist Health System completes final steps to become the first in South Central Texas to implement an eICU® program designed to improve critical care delivery and save lives. "eGuardian" utilizes the eICU® Program from Philips VISICU, that combines early warning software and remote monitoring to connect off-site critical care physicians and nurses to ICU patients around the clock.

18 May 2010

Senesco Technologies third-quarter net loss increases to $5.28M

Senesco Technologies, Inc. today announced financial results for the three and nine months ended March 31, 2010.

18 May 2010

Varian Medical Systems launches fully-integrated ProBeam proton therapy system at 2010 PT-COG

Varian Medical Systems is introducing the fully-integrated ProBeam™ proton therapy system at the 2010 Particle Therapy Co-operative Group (PT-COG) meeting here this week. The ProBeam system incorporates imaging, gating, robotic patient positioning, treatment planning and oncology information software to enhance treatment quality for patients and workflow efficiency for clinicians.

18 May 2010

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

Allos Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder, a form of bladder cancer. The Company is currently investigating pralatrexate in a Phase 2 clinical study in patients with advanced or metastatic relapsed TCC of the urinary bladder.

18 May 2010

Warnings about a ruined appearance is best way to reduce tanning salon visits

What's the most effective way to convince young women to cut back on their indoor tanning, a habit that hikes their risk of melanoma, the deadliest form of skin cancer, by 75 percent? Warn them that it will cause leathery, wrinkled skin.

18 May 2010

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

Authors of the report, "Cellphones and Brain Tumors: 15 Reasons for Concern, Science, Spin and the Truth Behind Interphone" have released a technical analysis of the long-awaited Interphone Study published today in the International Journal of Epidemiology.

18 May 2010

TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M

TapImmune Inc., a Nevada corporation, announced today that the Company entered into a definitive purchase agreement on May 17, 2010 with accredited investors to place Senior Secured Convertible Notes totaling $1.53 million. The net proceeds of the financing will be used for the development of certain partnerships and for general working capital.

From Evident Corporation - Life Sciences 18 May 2010

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

Tengion Inc. today reported its financial results for the quarter ended March 31, 2010 and provided a corporate and clinical development update.

18 May 2010

First Edition: May 18, 2010

Kaiser Health News staff writer Jordan Rau, working in collaboration with The Washington Post, reports on Provo, Utah: "If there is any place that should have medical spending under control, this is it" (Kaiser Health News).

18 May 2010

EDAP first-quarter revenue decreases to EUR 4.3 million

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today financial results for the first quarter ended March 31, 2010.

18 May 2010

President's Cancer Panel recommends home filtering devices to decrease exposure to cancer-causing agents

In its official annual report, the President's Cancer Panel is recommending that people use home filtering devices to decrease exposure to cancer-causing agents.

18 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended March 31, 2010.

18 May 2010

Cancer News and Research

Latest Cancer News and Research

Cincinnati Children's Hospital Medical Center launches REGID

Researchers discover biological pathway signature of ccRCC

Where are Australia’s missing hepatitis C cases?

WPI, Cerus announce positive results from study of INTERCEPT Blood System to inactivate XMRV

Senesco to present preclinical data of SNS-01 at ASGCT Annual Meeting

Baptist Health System implements eGuardian eICU Program from Philips VISICU

Senesco Technologies third-quarter net loss increases to $5.28M

Varian Medical Systems launches fully-integrated ProBeam proton therapy system at 2010 PT-COG

FDA grants orphan drug designation to pralatrexate for treatment of advanced TCC of urinary bladder

Warnings about a ruined appearance is best way to reduce tanning salon visits

Interphone Study underestimates risk of brain cancer, says International EMF Collaborative

TapImmune announces definitive purchase agreement for Senior Secured Convertible Notes totaling $1.53M

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Tengion reports net loss attributable to common stockholders of $14.33 per share for first-quarter 2010

First Edition: May 18, 2010

EDAP first-quarter revenue decreases to EUR 4.3 million

President's Cancer Panel recommends home filtering devices to decrease exposure to cancer-causing agents

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

Simcere Pharmaceutical first-quarter total revenue up 3.7% to $67.2 million

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in